RLY-4008
Relay Therapeutics
['rly-4008', 'focus trial', 'refocus']
precision oncology works! exciting data on fgfr2i rly-4008 refocus trial showing rr 88%, with less tox than panfgfr2i, presented #esmo22. trial open - accepting all comers with fgfr2mut/amp/rearr as well as cholangio in any setting. 
Early Phase Trials Medical oncologist + Translational Researcher @kinghorncancer and @CMRI  Clinical Lecturer @Sydney_Uni.